论文部分内容阅读
选择糖尿病LEADDP患者176例,分为血塞通治疗组和对照组,均以饮食及胰岛素控制血糖。观察两组治疗前后足部病变改善、下肢动脉彩色,多普勒血液动力学改变以及治疗过程中出现的副作用。结果:治疗组总有效率显著高于对照组(P<0·01),彩色多普勒血液动力学改变有显著性差异(P<0·05,P<0·01),无明显的不良反应。结论:血塞通为一种安全、有效的治疗糖尿病LEADDP的药物。
176 cases of diabetic patients with LEADDP were divided into Xuesaitong treatment group and control group, all with diet and insulin control blood sugar. The improvement of foot lesion, color and Doppler hemodynamics of lower extremity artery and the side effects during treatment were observed before and after treatment. Results: The total effective rate in the treatment group was significantly higher than that in the control group (P <0.01), and the color Doppler hemodynamic changes were significantly different (P <0.05, P <0.01) reaction. Conclusion: Xuesaitong is a safe and effective drug for the treatment of diabetic LEADDP.